East Aurora, NY, United States of America

Anatoli Gleiberman

USPTO Granted Patents = 5 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 50(Granted Patents)


Company Filing History:


Years Active: 2016-2023

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Anatoli Gleiberman

Introduction

Anatoli Gleiberman is a notable inventor based in East Aurora, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 5 patents, Gleiberman's work focuses on utilizing toll-like receptor agonists to combat cancer and protect liver health.

Latest Patents

Gleiberman's latest patents include groundbreaking methods and agents for treating cancer in Toll-Like Receptor 5-expressing tissues. His inventions involve the use of a Toll-Like Receptor agonist, such as flagellin, which has shown promise in enhancing cancer treatment efficacy. Additionally, his patents address the protection of the liver from toxicity associated with cancer treatments, showcasing his commitment to improving patient outcomes.

Career Highlights

Anatoli Gleiberman is associated with Cleveland Biolabs, Inc., where he continues to advance his research in cancer therapies. His work has garnered attention in the scientific community, contributing to the understanding of immune responses in cancer treatment.

Collaborations

Gleiberman has collaborated with esteemed colleagues, including Lyudmila Burdelya and Andrei V Gudkov. These partnerships have further enriched his research and expanded the impact of his inventions in the medical field.

Conclusion

Anatoli Gleiberman's innovative work in cancer treatment through toll-like receptor agonists highlights his dedication to advancing medical science. His contributions are paving the way for new therapeutic approaches that could significantly benefit patients facing cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…